LEGEND BIOTECH CORP (LEGN)
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Wolfspeed Appoints Seasoned Investor Relations Leader to Enhance Engagement with the Investment Community
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading
Adani Enterprises and Jabil Target a Strategic Alliance to Build AI Data Center Infrastructure Platform in India
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
MarineMax Expands Premium Portfolio with Exclusive Distribution of Newly Launched Ducari Yachts
Humacytes Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
Chaince Digital Announces Launch of USDC Yield Vault on Morpho Curated by AlphaPing